Unknown

Dataset Information

0

A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.


ABSTRACT: Given the poor outcomes of relapsed aggressive lymphomas and preclinical data suggesting that ?2·5 ?mol/l concentrations of vorinostat synergize with both etoposide and platinums, we hypothesized that pulse high-dose vorinostat could safely augment the anti-tumour activity of (R)ICE [(rituximab), ifosphamide, carboplatin, etoposide] chemotherapy. We conducted a phase I dose escalation study using a schedule with oral vorinostat ranging from 400 mg/d to 700 mg bid for 5 d in combination with the standard (R)ICE regimen (days 3, 4 and 5). Twenty-nine patients [median age 56 years, median 2 prior therapies, 14 chemoresistant (of 27 evaluable), 2 prior transplants] were enrolled and treated. The maximally tolerated vorinostat dose was defined as 500 mg twice daily × 5 d. Common dose limiting toxicities included infection (n = 2), hypokalaemia (n = 2), and transaminitis (n = 2). Grade 3 related gastrointestinal toxicity was seen in 9 patients. The median vorinostat concentration on day 3 was 4·5 ?mol/l (range 4·2-6·0 ?mol/l) and in vitro data confirmed the augmented antitumour and histone acetylation activity at these levels. Responses were observed in 19 of 27 evaluable patients (70%) including 8 complete response/unconfirmed complete response. High-dose vorinostat can be delivered safely with (R)ICE, achieves potentially synergistic drug levels, and warrants further study, although adequate gastrointestinal prophylaxis is warranted.

SUBMITTER: Budde LE 

PROVIDER: S-EPMC3618618 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.

Budde Lihua E LE   Zhang Michelle M MM   Shustov Andrei R AR   Pagel John M JM   Gooley Ted A TA   Oliveira George R GR   Chen Tara L TL   Knudsen Nancy L NL   Roden Jennifer E JE   Kammerer Britt E BE   Frayo Shani L SL   Warr Thomas A TA   Boyd Thomas E TE   Press Oliver W OW   Gopal Ajay K AK  

British journal of haematology 20130129 2


Given the poor outcomes of relapsed aggressive lymphomas and preclinical data suggesting that ≥2·5 μmol/l concentrations of vorinostat synergize with both etoposide and platinums, we hypothesized that pulse high-dose vorinostat could safely augment the anti-tumour activity of (R)ICE [(rituximab), ifosphamide, carboplatin, etoposide] chemotherapy. We conducted a phase I dose escalation study using a schedule with oral vorinostat ranging from 400 mg/d to 700 mg bid for 5 d in combination with the  ...[more]

Similar Datasets

| S-EPMC10111346 | biostudies-literature
| S-EPMC8457616 | biostudies-literature
| S-EPMC6314205 | biostudies-literature
| S-EPMC5124468 | biostudies-literature
| S-EPMC10803178 | biostudies-literature
| S-EPMC3301422 | biostudies-other
| S-EPMC7035866 | biostudies-literature
| S-EPMC4283736 | biostudies-literature
| S-EPMC9395483 | biostudies-literature
| S-EPMC8993776 | biostudies-literature